Novartis Announced The Us Food And Drug Administration (Fda) Granted Approval For Tafinlar (Dabrafenib) + Mekinist (Trametinib) For The Treatment Of Paediatric Patients 1 Year Of Age And Older With Low-Grade Glioma (Lgg) With A Braf V600E Mutation Who Require Systemic Therapy. The Fda Also Approved Liquid Formulations Of Tafinlar And Mekinist, Marking The First Time A Braf/Mek Inhibitor Has Been Developed In A Formulation Suitable For Patients As Young As One Year Of Age. These Approvals Make Tafinlar + Mekinist The First And Only Approved Combination Targeted Therapy To Treat Paediatric Patients With Braf V600E Lgg.
